Embodiments of bridged tetrahydroisoquinolines and methods for their use in selectively inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 are disclosed. The disclosed compounds have a structure according to general formula I or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein “” represents a single or double bond, R.sup.1 is hydrogen, halogen, lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R.sup.a is hydrogen, —CH.sub.2R.sup.2, R.sup.3, or —SO.sub.2R.sup.4; R.sup.2 is lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R.sup.3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R.sup.4 is lower aliphatic, or substituted or unsubstituted aryl; and R.sup.5 is hydrogen, halogen, or lower aliphatic.

Embodiments of bridged tetrahydroisoquinolines and methods for their use in selectively inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 are disclosed. The disclosed compounds have a structure according to general formula I or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein “” represents a single or double bond, R.sup.1 is hydrogen, halogen, lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R.sup.a is hydrogen, —CH.sub.2R.sup.2, R.sup.3, or —SO.sub.2R.sup.4; R.sup.2 is lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R.sup.3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R.sup.4 is lower aliphatic, or substituted or unsubstituted aryl; and R.sup.5 is hydrogen, halogen, or lower aliphatic.

A compound of Formula I and formulations including such a compound may be used for the reduction of infestation with ectoparasites, in particular ectoparasites of the insect class, including fleas and mosquitoes, and/or ectoparasites of the arachnid class, including ticks and mites, etc. Methods for controlling ectoparasites and/or formulations including such compounds may include use as a repellent, and/or application to a mammal, e.g., a human, dog, cat, cattle, horse, or sheep, or to an object or a fabric. The form may be a topical formulation, a shampoo composition, a cleansing composition, or a treatment composition, preferably a lotion, cream, ointment, gel, foam, patch, powder, solid, sponge, tape, vapor, paste, tincture, or spray.

A compound of Formula I and formulations including such a compound may be used for the reduction of infestation with ectoparasites, in particular ectoparasites of the insect class, including fleas and mosquitoes, and/or ectoparasites of the arachnid class, including ticks and mites, etc. Methods for controlling ectoparasites and/or formulations including such compounds may include use as a repellent, and/or application to a mammal, e.g., a human, dog, cat, cattle, horse, or sheep, or to an object or a fabric. The form may be a topical formulation, a shampoo composition, a cleansing composition, or a treatment composition, preferably a lotion, cream, ointment, gel, foam, patch, powder, solid, sponge, tape, vapor, paste, tincture, or spray.

##STR00001##

Compounds of formula (I), formula (II), or formula (III) and their use with a neurological or psychiatric disorder, mediated by Kv11.1-3.1 containing potassium channels, including schizophrenia, are disclosed.

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M.sub.1 (mAChR M.sub.1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

The present invention provides azepino-indoles and other heterocycles and methods of using the compounds for treating brain disorders.

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.